# EDGAR Filing Document

**Accession Number:** 0001817760
**File Stem:** 0001104659-25-111274
**Filing Date:** 2025-11
**Character Count:** 112698
**Document Hash:** 07091a8d08c9c5a276568984448425c5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-111274.hdr.sgml**: 20251113

**ACCESSION NUMBER**: 0001104659-25-111274

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 72

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251113

**DATE AS OF CHANGE**: 20251113

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SmartKem, Inc.
- **CENTRAL INDEX KEY:** 0001817760
- **STANDARD INDUSTRIAL CLASSIFICATION:** SEMICONDUCTORS & RELATED DEVICES [3674]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 851083654
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42115
- **FILM NUMBER:** 251478401

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** MANCHESTER TECHNOLOGY CENTER
- **STREET 2:** HEXAGON TOWER, DELAUNAYS ROAD, BLACKLEY
- **CITY:** MANCHESTER
- **PROVINCE COUNTRY:** X0
- **ZIP:** M9 8GQ
- **BUSINESS PHONE:** 011-44-161-721-1514

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** MANCHESTER TECHNOLOGY CENTER
- **STREET 2:** HEXAGON TOWER, DELAUNAYS ROAD, BLACKLEY
- **CITY:** MANCHESTER
- **PROVINCE COUNTRY:** X0
- **ZIP:** M9 8GQ

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Parasol Investments Corp
- **DATE OF NAME CHANGE:** 20200710

?xml version='1.0' encoding='ASCII'? SmartKem, Inc._September 30, 2025

[**Table of Contents**](#TOC)

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

**(Mark One)**

**☒** **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934**

**For the quarterly period ended September 30, 2025**

**or**

**☐** **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934**

**For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;** 

**Commission File Number: 001-42115** 

## SmartKem, Inc.
**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **85-1083654** |
| **(State or other jurisdiction of** | **(I.R.S. Employer** |
| **incorporation or organization)** | **Identification Number)** |

---

**Manchester Technology Centre, Hexagon Tower.**

**Delaunays Road, Blackley**

**Manchester, M9 8GQ U.K.**

**(Address of Principal Executive Offices)**

**011-44-161-721-1514**

**(Registrant's telephone number)**

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Title of each class** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Trading Symbol(s)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Name of exchange on which registered** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common Stock, par value $0.0001 per share | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SMTK | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer<br>| ☐ | Accelerated filer<br>| ☐ |
| Non-accelerated filer<br>| ☒ | Smaller reporting company<br>| ☒ |
|  |  | Emerging growth company<br>| ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 11, 2025, there were 6,134,963 shares of the registrant's common stock outstanding.

------

[**Table of Contents**](#TOC)

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
|  |  | **Page** |
| [**Part I**](#PARTIFINANCIALINFORMATION_662395) | [**Financial Information**](#PARTIFINANCIALINFORMATION_662395) | 3 |
| [Item 1.](#Item1FinancialStatements_466030) | [Financial Statements](#Item1FinancialStatements_466030) | 3 |
|  | [Unaudited Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024](#BalanceSheet) | 3 |
|  | [Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2025 and 2024](#CondensedConsolidatedStatementsofCompreh) | 4 |
|  | [Unaudited Condensed Consolidated Statements of Stockholders' (Deficit) / Equity for the three and nine months ended September 30, 2025 and 2024](#CondensedConsolidatedstatementofStockhol) | 5-6 |
|  | [Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024](#CondensedConsolidatedStatementsofCashFlo) | 7 |
|  | [Notes to the Unaudited Interim Condensed Consolidated Financial Statements](#NotestoCondensedConsolidatedFS) | 8-20 |
| [Item 2.](#Item2ManagementsDiscussionandAnalysisofF) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#Item2ManagementsDiscussionandAnalysisofF) | 21 |
| [Item 3.](#Item3QuantitativeandQualitativeDiscl) | [Quantitative and Qualitative Disclosures about Market Risk](#Item3QuantitativeandQualitativeDiscl) | 26 |
| [Item 4.](#Item4ControlsandProcedures_889551) | [Controls and Procedures](#Item4ControlsandProcedures_889551) | 26 |
| [**Part II**](#PARTIIOTHERINFORMATION_911527) | [**Other Information**](#PARTIIOTHERINFORMATION_911527) | 27 |
| [Item 1.](#Item1LegalProceedings_451676) | [Legal Proceedings](#Item1LegalProceedings_451676) | 27 |
| [Item 1A.](#Item1ARiskFactors) | [Risk Factors](#Item1ARiskFactors) | 27 |
| [Item 2.](#Item2UnregisteredSaleofEquity) | [Unregistered Sales of Equity Securities and Use of Proceeds](#Item2UnregisteredSaleofEquity) | 27 |
| [Item 3.](#Item3DefaultsUponSeniorSecurities) | [Defaults Upon Senior Securities](#Item3DefaultsUponSeniorSecurities) | 27 |
| [Item 4.](#Item4MineSafetyDisclosures) | [Mine Safety Disclosures](#Item4MineSafetyDisclosures) | 27 |
| [Item 5.](#Item5OtherInformation_7756) | [Other Information](#Item5OtherInformation_7756) | 27 |
| [Item 6.](#Item6Exhibits_881771) | [Exhibits](#Item6Exhibits_881771) | 27 |
| [Exhibit Index](#EXHIBITINDEX_292507) | [Exhibit Index](#EXHIBITINDEX_292507) | 28 |
| [Signatures](#SIGNATURES_371543) |  | 29 |

---

[**Table of Contents**](#TOC)

#### Item 1. Financial Statements

#### SMARTKEM, INC.

#### Condensed Consolidated Balance Sheets
**(Unaudited)**

(in thousands, except number of shares and per share data)

---

| | | |
|:---|:---|:---|
|  | **September 30,** <br>**2025** | **December 31,** <br>**2024** |
| **Assets** |  |  |
| &nbsp;&nbsp;Current assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $881 | $7141 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development tax credit receivable | 404 | 519 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 1079 | 849 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 2364 | 8509 |
| &nbsp;&nbsp;&nbsp;&nbsp;Property, plant and equipment, net | 221 | 269 |
| &nbsp;&nbsp;&nbsp;&nbsp;Right-of-use assets, net | 663 | 120 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets, non-current |  | 6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total assets** | $3248 | $8904 |
| **Liabilities and stockholders' (deficit) / equity** |  |  |
| &nbsp;&nbsp;Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | $4890 | $1791 |
| &nbsp;&nbsp;&nbsp;&nbsp;Lease liabilities, current | 274 | 47 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | 660 | 450 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 5824 | 2288 |
| &nbsp;&nbsp;&nbsp;&nbsp;Lease liabilities, non-current | 376 | 25 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 6200 | 2313 |
| Contingencies (Note 7) |  |  |
| **Stockholders' (deficit) / equity:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, 0 and 856 shares issued and outstanding, at September 30, 2025 and December 31, 2024, respectively |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock, par value $0.0001 per share, 300,000,000 shares authorized, 5,605,043 and 3,590,217 shares issued and outstanding, at September 30, 2025 and December 31, 2024, respectively | 1 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 123495 | 122316 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (3374) | (1105) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (123074) | (114620) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' (deficit) / equity | (2952) | 6591 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities and stockholders' (deficit) / equity** | $3248 | $8904 |

---

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

[**Table of Contents**](#TOC)

#### SMARTKEM, INC.

#### Condensed Consolidated Statements of Operations and Comprehensive Loss
**(Unaudited)**

(in thousands, except number of shares and per share data)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,**  | **Three Months Ended September 30,**  | **Nine Months Ended September 30,**  | **Nine Months Ended September 30,**  |
|  | **2025** | **2024** | **2025** | **2024** |
| Revenue | $81 | $— | $136 | $40 |
| Cost of revenue | 5 |  | 34 | 32 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 76 |  | 102 | 8 |
| Other operating income | 181 | 287 | 711 | 725 |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;Research and development | 2056 | 1504 | 5979 | 3938 |
| &nbsp;&nbsp;General and administrative | 1331 | 1578 | 5700 | 4784 |
| &nbsp;&nbsp;&nbsp;&nbsp;(Gain) / loss on foreign currency transactions | 59 | 43 | (167) | 75 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 3446 | 3125 | 11512 | 8797 |
| Loss from operations | (3189) | (2838) | (10699) | (8064) |
| Non-operating income / (expense) |  |  |  |  |
| &nbsp;&nbsp;Gain / (loss) on foreign currency transactions | (732) |  | 2207 | (249) |
| &nbsp;&nbsp;Change in fair value of the warrant liability |  |  |  | 672 |
| &nbsp;&nbsp;Interest income / (expense) | 1 | (4) | 14 | 5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total non-operating income / (expense) | (731) | (4) | 2221 | 428 |
| Loss before income taxes | (3920) | (2842) | (8478) | (7636) |
| &nbsp;&nbsp;Income tax refund / (expense) |  |  | 24 | (1) |
| Net loss | $(3920) | $(2842) | $(8454) | $(7637) |
| Preferred stock deemed dividends |  |  |  | (7094) |
| Net loss attributed to common stockholders | $(3920) | $(2842) | $(8454) | $(14731) |
| Weighted average shares outstanding - basic and diluted | 8782766 | 3308975 | 7842215 | 3068110 |
| Common share data: |  |  |  |  |
| Basic net loss per common share | $(0.45) | $(0.86) | $(1.08) | $(2.49) |
| Diluted net loss per common share | (0.45) | (0.86) | (1.08) | (4.80) |
| Dividend per common share |  |  |  | (2.31) |
| Net loss | $(3920) | $(2842) | $(8454) | $(7637) |
| Other comprehensive loss: |  |  |  |  |
| &nbsp;&nbsp;Foreign currency translation | 800 | 125 | (2269) | 281 |
| Total comprehensive loss | $(3120) | $(2717) | $(10723) | $(7356) |

---

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

[**Table of Contents**](#TOC)

#### SMARTKEM, INC.

#### Condensed Consolidated Statements of Stockholders' (Deficit) / Equity
(Unaudited)

#### (in thousands, except share data)

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Preferred Stock** | **Preferred Stock** | **Common stock** | **Common stock** | | | | |
|  | **$0.0001 par value** | **$0.0001 par value** | **$0.0001 par value** | **$0.0001 par value** | | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Additional**<br>**paid-in**<br>**capital** | **Accumulated other**<br>**comprehensive**<br>**income / (loss)** | <br>**Accumulated**<br>**deficit** | **Total**<br>**stockholders'**<br>**(deficit) / equity** |
| **Balance at January 1, 2025** | 856 | $— | 3590217 | $— | $122316 | $(1105) | $(114620) | $6591 |
| Stock-based compensation expense |  |  |  |  | 250 |  |  | 250 |
| Issuance of common stock to vendor |  |  | 30000 |  | 85 |  |  | 85 |
| Foreign currency translation adjustment |  |  |  |  |  | (1005) |  | (1005) |
| Net loss |  |  |  |  |  |  | (2134) | (2134) |
| **Balance at March 31, 2025** | 856 | $— | 3620217 | $— | $122651 | $(2110) | $(116754) | $3787 |
| Stock-based compensation expense |  |  |  |  | 260 |  |  | 260 |
| Issuance of common stock to vendor |  |  | 130000 |  | 290 |  |  | 290 |
| Conversion of Preferred stock into common stock | (856) |  | 690788 |  |  |  |  |  |
| Exercise of warrants into common stock |  |  | 160 |  |  |  |  |  |
| Foreign currency translation adjustment |  |  |  |  |  | (2064) |  | (2064) |
| Net loss |  |  |  |  |  |  | (2400) | (2400) |
| **Balance at June 30, 2025** |  | $— | 4441165 | $— | $123201 | $(4174) | $(119154) | $(127) |
| Stock-based compensation expense |  |  |  |  | 261 |  |  | 261 |
| Issuance of common stock to vendor |  |  | 30000 |  | 34 |  |  | 34 |
| Exercise of warrants into common stock |  |  | 1133878 | 1 | (1) |  |  |  |
| Foreign currency translation adjustment |  |  |  |  |  | 800 |  | 800 |
| Net loss |  |  |  |  |  |  | (3920) | (3920) |
| **Balance at September 30, 2025** |  | $— | 5605043 | $1 | $123495 | $(3374) | $(123074) | $(2952) |

---

[**Table of Contents**](#TOC)

#### SMARTKEM, INC.

#### Condensed Consolidated Statements of Stockholders' (Deficit) / Equity (continued)
(Unaudited)

#### (in thousands, except share data)

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Preferred Stock** | **Preferred Stock** | **Common stock** | **Common stock** | | | | |
|  | **$0.0001 par value** | **$0.0001 par value** | **$0.0001 par value** | **$0.0001 par value** | | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Additional**<br>**paid-in**<br>**capital** | **Accumulated other**<br>**comprehensive**<br>**income / (loss)** | <br>**Accumulated**<br>**deficit** | **Total**<br>**stockholders'**<br>**equity** |
| **Balance at January 1, 2024** | 13765 | $— | 889668 | $— | $104757 | $(1578) | $(95066) | $8113 |
| Stock-based compensation expense |  |  |  |  | 107 |  |  | 107 |
| Issuance of stock awards |  |  | 3400 |  | 21 |  |  | 21 |
| Issuance of common stock to vendor |  |  | 50000 |  | 53 |  |  | 53 |
| Conversion of Preferred stock into common stock | (3817) |  | 436294 |  |  |  |  |  |
| Exchange of Preferred stock into common stock warrants | (6356) |  |  |  |  |  |  |  |
| Deemed dividend on extinguishment of Preferred stock |  |  |  |  | 7069 |  | (7094) | (25) |
| Cashless exercise of warrants into common stock |  |  | 388 |  |  |  |  |  |
| Foreign currency translation adjustment |  |  |  |  |  | (18) |  | (18) |
| Net loss |  |  |  |  |  |  | (1696) | (1696) |
| **Balance at March 31, 2024** | 3592 | $— | 1379750 | $— | $112007 | $(1596) | $(103856) | $6555 |
| Stock-based compensation expense |  |  |  |  | 207 |  |  | 207 |
| Issuance of common stock to vendor |  |  | 50000 |  | 48 |  |  | 48 |
| Conversion of Preferred stock into common stock | (2486) |  | 284150 |  |  |  |  |  |
| Exercise of warrants into common stock |  |  | 8000 |  | 3 |  |  | 3 |
| Fair value of warrants reclassified from liability to equity |  |  |  |  | 700 |  |  | 700 |
| Foreign currency translation adjustment |  |  |  |  |  | 174 |  | 174 |
| Net loss |  |  |  |  |  |  | (3099) | (3099) |
| **Balance at June 30, 2024** | 1106 | $— | 1721900 | $— | $112965 | $(1422) | $(106955) | $4588 |
| Stock-based compensation expense |  |  |  |  | 257 |  |  | 257 |
| Issuance of common stock to vendor |  |  | 30000 |  | 152 |  |  | 152 |
| Conversion of Preferred stock into common stock | (250) |  | 28572 |  |  |  |  |  |
| Foreign currency translation adjustment |  |  |  |  |  | 125 |  | 125 |
| Net loss |  |  |  |  |  |  | (2842) | (2842) |
| **Balance at September 30, 2024** | 856 | $— | 1780472 | $— | $113374 | $(1297) | $(109797) | $2280 |

---

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

[**Table of Contents**](#TOC)

#### SMARTKEM, INC.

#### Condensed Consolidated Statements of Cash Flows
(Unaudited)

#### (in thousands)

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended September 30,**  | **Nine Months Ended September 30,**  |
|  | **2025** | **2024** |
| **Cash flow from operating activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss | $(8454) | $(7637) |
| &nbsp;&nbsp;Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 171 | 194 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | 769 | 592 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of common stock to vendor | 409 | 253 |
| &nbsp;&nbsp;&nbsp;&nbsp;Right-of-use asset amortization | 182 | 201 |
| &nbsp;&nbsp;&nbsp;&nbsp;(Loss) / gain on foreign currency transactions | (2374) | 283 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of the warrant liability |  | (672) |
| &nbsp;&nbsp;Change in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable |  | 269 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development tax credit receivable | 148 | (499) |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | (186) | 43 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-current assets |  | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | 2984 | 149 |
| &nbsp;&nbsp;&nbsp;&nbsp;Lease liabilities | (145) | (166) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | 175 | (20) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | (6321) | (7009) |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of property, plant and equipment | (105) | (75) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used by investing activities | (105) | (75) |
| **Cash flow from financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the exercise of warrants |  | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities |  | 3 |
| Effect of exchange rate changes on cash | 166 | 28 |
| Net change in cash | (6260) | (7053) |
| Cash, beginning of period | 7141 | 8836 |
| Cash, end of period | $881 | $1783 |
| **Supplemental disclosure of cash and non-cash investing and financing activities** |  |  |
| &nbsp;&nbsp;Issuance of common shares for consulting services | $409 | $253 |
| &nbsp;&nbsp;Right-of-use asset and lease liability additions | $706 | $82 |

---

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

[**Table of Contents**](#TOC)

**SMARTKEM, INC.**

**Notes to the Unaudited Condensed Consolidated Financial Statements**

&nbsp;&nbsp;&nbsp;&nbsp;1. **GENERAL** 

***Organization***

SmartKem, Inc. ("SmartKem" or the "Company") a Delaware corporation, formerly known as Parasol Investments Corporation ("Parasol"), was formed on May 13, 2020, and is the successor, as discussed below, of SmartKem Limited, which was formed under the Laws of England and Wales. The Company was founded as a "shell" company registered under the Exchange Act, with no specific business plan or purpose until it began operating the business of SmartKem Limited following the closing of the Exchange described below.

On February 23, 2021, Parasol entered into a Securities Exchange Agreement (the "Exchange Agreement"), with SmartKem Limited. Pursuant to the Exchange Agreement all of the equity interests in SmartKem Limited, except certain deferred shares which had no economic or voting rights and which were purchased by Parasol for an aggregate purchase price of $1.40, were exchanged for shares of Parasol common stock, par value $0.0001 per share ("common stock"), and SmartKem Limited became a wholly owned subsidiary of Parasol (the "Exchange").

As a result of the Exchange, Parasol legally acquired the business of SmartKem Limited, and continues as the existing business operations of SmartKem Limited as a public reporting company under the name SmartKem, Inc.

***Business***

The Company is seeking to change the world of electronics with a new class of transistor developed using its proprietary advanced semiconductor materials. The Company's TRUFLEX® semiconductor polymers enable low temperature printing processes that are compatible with existing manufacturing infrastructure to deliver low-cost, high-performance displays. The Company's semiconductor platform can be used in a range of display technologies including MicroLED, LCD and AMOLED, as well as in applications in advanced computer and AI chip packaging, sensors, and logic.

The Company designs and develops its materials at its research and development facility in Manchester, UK and operates a field application office in Hsinchu, Taiwan, close to its collaboration partner, The Industrial Technology Research Institute of Taiwan ("ITRI"), which provides product prototyping services, with its collaboration partners, the Company is developing a commercial-scale production process and Electronic Design Automation (EDA) tools for its materials to demonstrate the commercial viability of manufacturing a new generation of displays using the Company's materials. The Company has an extensive IP portfolio including 140 granted patents across 17 patent families, 14 pending patents and 40 codified trade secrets.

#### Risk and Uncertainties
The Company's activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company's business plan. The Company is subject to risks that are common to companies in the development stage, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology and compliance with regulatory requirements.

The Company has entered into annual framework services agreements with CPI Innovation Services Limited ("CPIIS"), the commercial trading company for the Centre for Product Innovation ("CPI"), pursuant to which the Company purchases services consisting primarily of access to CPI process equipment required for fabrication as well as access to CPI staff with specific skills, to the extent required, at specified costs, including a minimum annual spending requirement. The Company's most current agreement with CPIIS expired on March 31, 2025, but has been extended as described below.

In the fourth quarter of 2024, CPIIS advised the Company that it intended to reduce the facility's operating costs by, among other things, consolidating its clean rooms and seeking to pass more of its operating costs to users including the Company. Subsequent to March 3, 2025, the Company entered into a number of short-term extensions of its CPIIS agreement pursuant to which the term of the current CPIIS agreement has been extended

[**Table of Contents**](#TOC)

**SMARTKEM, INC.**

**Notes to the Unaudited Condensed Consolidated Financial Statements**

to December 31, 2025. Under the terms of the extensions, the Company agreed to an increase in its share of the costs of the CPI facility during the extension period. As a result, subsequent to March 31, 2025, the Company's costs related to the CPI facility increased significantly. The Company has not paid CPIIS the amounts due with respect to the CPI facility and is currently disputing the terms of that agreement. As a result, the Company does not have access to the CPI facilities and has ceased all prototyping operations at CPI.

The Company will continue to explore options to perform its prototyping services. The Company believes that adequate alternative sites are available for that purpose and is assessing whether to continue prototyping activities on its own or to contract for such services with a third party, potentially in Taiwan. Subject to the receipt of adequate capital financing, in the event that the Company decides to move its prototyping operation to an alternative facility, the Company believes that the move would take between two and nine months, depending on equipment availability and any required facility modifications, during which time the Company would incur additional costs to prepare the new facility and install any necessary equipment. In such event, the Company intends to schedule its prototyping activities to minimize any disruption to those operations.

The Company and ITRI have been negotiating terms for a proposed multi-year agreement under which ITRI would upgrade its existing facilities to enable the Company to substantially undertake its product prototyping operations at ITRI's facility.

The Company has approximately 11 employees located at CPI. Even if the Company is able to locate a suitable replacement facility on acceptable terms, there is no assurance that the key employees at CPI would accept positions at a new facility, particularly if it is located remotely from the CPI facility. Even if the Company locates a suitable replacement facility, it is possible that the Company's ability to engage in product development, prototyping of demonstration products and process improvement activities may be significantly delayed as a result of the relocation of those functions. In the event that the Company moves its prototyping operations to ITRI's Taiwan facility, the Company expects that it would terminate the employment of the employees located at CPI.

As a result of the Company's need for additional capital, the Company has significantly curtailed its operations and delayed payments to its vendors as a part of its plan to conserve cash. Consequently, the Company's accounts payable have increased significantly since September 30, 2025. The Company will require significant additional capital in order to pay vendors and to resume normal operations.

*Jericho Transaction*

On October 6, 2025, the Company entered into a non-binding letter of intent (the "LOI") with Jericho Energy Ventures Inc. ("Jericho"), an energy innovation company, to pursue a potential business combination (the "Proposed Transaction"). Under the LOI, the Proposed Transaction would be structured as an all-stock business combination, effected through either a share exchange or statutory merger, pursuant to which the Company would be the surviving legal entity and would continue as a publicly listed company on The Nasdaq Stock Market ("Nasdaq") (such surviving company, the "Combined Company"). Upon the closing of the Proposed Transaction, Jericho stockholders would own 65% and Company stockholders prior to the Proposed Transaction would own 35% of the fully diluted issued and outstanding equity securities of the Combined Company, subject to adjustment in certain circumstances. Brian Williamson, the current chief executive officer of Jericho, would become the chief executive officer of the Combined Company, and the board of directors of the Combined Company would be reconstituted to include a majority of members designated by Jericho, subject to compliance with applicable requirements of Nasdaq and the Securities and Exchange Commission (the "SEC").

The LOI is non-binding, and there can be no assurance that the Company and Jericho will ultimately enter into a definitive agreement for the Proposed Transaction, that the Proposed Transaction will be consummated, or as to the timing or ultimate terms of any Proposed Transaction that may occur. Both the Company and Jericho will need significant additional capital to complete the negotiation of the Proposed Transaction, obtain any required stockholder approvals and ultimately complete the Proposed Transaction. The closing of the Proposed Transaction would be subject to significant closing conditions, including the negotiation of the definitive agreement, the satisfactory completion of due diligence, required board and stockholder approvals, and approval of continued listing by Nasdaq.

[**Table of Contents**](#TOC)

**SMARTKEM, INC.**

**Notes to the Unaudited Condensed Consolidated Financial Statements**

In the LOI, the Company and Jericho have agreed to a 60-day exclusivity period to negotiate the terms of a definitive agreement, which exclusivity period is terminable by either party under certain circumstances including, in the case of Jericho, if the Company does not purchase Jericho common shares having a value of at least $500,000 on or prior to November 30, 2025. So long as the LOI is still in effect, upon the earlier of (i) the Company's chief financial officer's good faith determination that the Company has regained compliance with Nasdaq's minimum stockholders' equity requirement and (ii) the Company's issuance of securities (including upon exercise of outstanding convertible securities) for aggregate gross proceeds of not less than $5,000,000, the Company will purchase from treasury Jericho common shares in an amount equal to the greater of (a) $500,000 and (b) 10% of the gross proceeds of such issuances, subject to a cap of $1,000,000. There can be no assurance that the circumstances necessary for the Company to satisfy the requirements for completion of the investment will occur.

#### Going Concern
The Company has incurred continuing losses including net losses of $8.5 million for the nine months ended September 30, 2025. The Company's cash as of September 30, 2025 was $0.9 million with net cash used in operating activities of $6.3 million for the nine months ended September 30, 2025. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research funding, further development of our technology and products and expenses related to the commercialization of our products.

The Company expects that its cash and cash equivalents of $0.9 million as of September 30, 2025 will not be sufficient to fund its operating expenses and capital expenditures for the 12 months from the issuance of these financial statements. In the event that the Company is unable to raise additional capital in the near term, it may have to curtail its operations or seek protection under applicable bankruptcy or insolvency laws. As described under Note 14. Subsequent Events - Senior Secured Loan, on October 31, 2025, the Company obtained $1,000,000 of bridge financing in exchange for the issuance of $1,100,000 principal amount of its Senior Secured Notes due April 30, 2026 (the "Senior Secured Notes") and five-year warrants to purchase up to 400,000 shares of common stock at an exercise price of $2.75 per share. There can be no assurance that the Company will be able to raise sufficient funds to repay the Senior Secured Notes which are secured by substantially all of the assets of the Company and its subsidiaries.

Beyond its near term need for capital, the Company's future viability will continue to be dependent on its ability to raise additional capital to fund its operations. The Company will need to obtain additional funds to satisfy its operational needs and to fund its sales and marketing efforts, research and development expenditures, and business development activities. Until such time, if ever, as the Company can generate sufficient cash through revenue, management's plans are to finance the Company's working capital requirements through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. If the Company raises additional funds by issuing equity securities, the Company's existing security holders will likely experience dilution. If the Company borrows money, the incurrence of indebtedness would result in increased debt service obligations and could require the Company to agree to operating and financial covenants that could restrict its operations. If the Company enters into a collaboration, strategic alliance or other similar arrangement, it may be forced to give up valuable rights. There can be no assurance however that such financing will be available in sufficient amounts, when and if needed, on acceptable terms or at all. The precise amount and timing of the funding needs cannot be determined accurately at this time, and will depend on a number of factors, including the market demand for the Company's products and services, the quality of product development efforts, management of working capital, and continuation of normal payment terms and conditions for purchase of services.

There is substantial doubt that the Company will be able to pay its obligations as they fall due, and this substantial doubt is not alleviated by management plans. The condensed consolidated financial statements as of September 30, 2025 have been prepared assuming that the Company will continue as a going concern. Accordingly, the consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.

[**Table of Contents**](#TOC)

**SMARTKEM, INC.**

**Notes to the Unaudited Condensed Consolidated Financial Statements**

#### Basis of Presentation
The unaudited interim condensed consolidated financial statements of the Company as of September 30, 2025 and December 31, 2024 and for the three and nine months ended September 30, 2025 and 2024 should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the "Annual Report"), which was filed with the SEC on March 31, 2025 and may also be found on the Company's website (www.smartkem.com). In these notes to the interim condensed consolidated financial statements the terms "us," "we" or "our" refer to the Company and its consolidated subsidiaries.

These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim reporting and with the SEC's instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all wholly owned subsidiaries and all significant inter-company accounts and transactions have been eliminated in consolidation. Amounts are presented in thousands, except number of shares and per share data.

The preparation of interim condensed consolidated financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company's results of operations, financial position and cash flows for the interim periods ended September 30, 2025 and 2024; however, certain information and footnote disclosures normally included in our audited consolidated financial statements included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company's results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period.

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

Other than the policies listed below, there have been no material changes to the Company's significant accounting policies as set forth in Note 3 Summary of Significant Accounting Policies to the consolidated financial statements included in the Company's Annual Report.

The Company records, when necessary, deemed dividends for: (i) the exchange of preferred shares for pre-funded warrants, based on the fair value of the pre-funded warrants in excess of the carrying value of the preferred shares and (ii) the amendment of preferred stock accounted for as an extinguishment, based on the fair value of the preferred stock immediately before and after the amendments.

***Management's Use of Estimates***

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The most significant estimates in the Company's consolidated financial statements relate to the valuation of common stock, fair value of stock options and fair value of warrant liabilities. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates.

***Segment Information***

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one operating segment: Semiconductor materials.

[**Table of Contents**](#TOC)

**SMARTKEM, INC.**

**Notes to the Unaudited Condensed Consolidated Financial Statements**

#### Recent Accounting Pronouncements
In December 2023, the FASB issued Accounting Standards Update (ASU) No. 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures which will require companies to make additional income tax disclosures. The pronouncement is effective for annual filings for the year ended December 31, 2025. The Company is still assessing the impact of the adoption of this standard but does not expect it to have a material impact on its results of operations, financial position or cash flows.

On November 2024, the FASB issued Accounting Standards Update (ASU) No. 2024-03, Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation Disclosures, Disaggregation of Income Statement Expenses, which requires public companies to disclose, in interim and annual reporting periods, additional information about certain expenses in the financial statements. The amendments in this pronouncement will be effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and is effective on either a prospective basis or retrospective basis. The Company is currently assessing the potential impacts of adoption on its consolidated financial statements and related disclosures.

3.&nbsp;&nbsp;&nbsp;&nbsp;PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consist of the following:

---

| | | |
|:---|:---|:---|
|  | **September 30,**  | **December 31,**  |
| ***(in thousands)*** | **2025** | **2024** |
| Prepaid insurance | $234 | $194 |
| Deferred research & development costs | 148 | 138 |
| Research grant receivable | 55 | 62 |
| Prepaid facility costs | 148 | 67 |
| VAT receivable | 55 | 319 |
| Prepaid software licenses | 81 | 66 |
| Advances and retainers | 335 |  |
| Other receivable and other prepaid expenses | 23 | 3 |
| &nbsp;&nbsp;Total prepaid expenses and other current assets | $1079 | $849 |

---

4.&nbsp;&nbsp;&nbsp;&nbsp;PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consist of the following:

---

| | | |
|:---|:---|:---|
|  | **September 30,**  | **December 31,**  |
| ***(in thousands)*** | **2025** | **2024** |
| Plant and equipment | $1777 | $1562 |
| Furniture and fixtures | 113 | 106 |
| Computer hardware and software | 106 | 98 |
|  | 1996 | 1766 |
| Less: Accumulated depreciation | (1775) | (1497) |
| &nbsp;&nbsp;Property, plant and equipment, net | $221 | $269 |

---

Depreciation expense was $170.6 thousand and $194.4 thousand for the nine months ended September 30, 2025 and 2024, respectively and is classified as research and development expense.

[**Table of Contents**](#TOC)

**SMARTKEM, INC.**

**Notes to the Unaudited Condensed Consolidated Financial Statements**

5.&nbsp;&nbsp;&nbsp;&nbsp;ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consist of the following:

---

| | | |
|:---|:---|:---|
|  | **September 30,**  | **December 31,**  |
| ***(in thousands)*** | **2025** | **2024** |
| Accounts payable - trade | $4031 | $843 |
| Payroll liabilities | 417 | 397 |
| VAT payable |  | 287 |
| Accrued expenses – audit & accounting fees |  | 106 |
| Accrued expenses – technical service fees | 314 |  |
| Accrued expenses – other | 128 | 158 |
| Total accounts payable and accrued expenses | $4890 | $1791 |

---

6.&nbsp;&nbsp;&nbsp;&nbsp;LEASES

The Company has operating leases consisting of office space, lab space and equipment with remaining lease terms of 1 to 3 years, subject to certain renewal options as applicable.

The Company evaluates the nature of each lease at the inception of an arrangement to determine whether it is an operating or financing lease and recognizes the right of use asset and lease liability based on the present value of future minimum lease payments over the expected lease term. The Company's leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments.

On May 22, 2025, the Company renewed its lease for research & development, engineering, testing and corporate offices in Manchester, England. The renewed lease term expires in 2028 with an option for the Company to end the lease in 2027.

On July 14, 2025, the Company entered into a sublease agreement for its office in Taoyuan City, Taiwan. The lease term expires in 2028 and can be terminated with 60 days' notice.

The Company is not the lessor in any lease agreement, and no related party transactions for lease arrangements have occurred.

The table below presents certain information related to the lease costs for the Company's operating leases for the periods ended:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,**  | **Three Months Ended September 30,**  | **Nine Months Ended September 30,**  | **Nine Months Ended September 30,**  |
| ***(in thousands)*** | **2025** | **2024** | **2025** | **2024** |
| Operating lease cost | $83 | $58 | $224 | $193 |
| Short-term lease cost | 13 | 5 | 25 | 11 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total lease cost | $96 | $63 | $249 | $204 |

---

The total lease cost is included in the unaudited condensed consolidated statements of operations as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,**  | **Three Months Ended September 30,**  | **Nine Months Ended September 30,**  | **Nine Months Ended September 30,**  |
| ***(in thousands)*** | **2025** | **2024** | **2025** | **2024** |
| Research and development | $95 | $58 | $243 | $193 |
| General and administrative | 1 | 5 | 6 | 11 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total lease cost | $96 | $63 | $249 | $204 |

---

[**Table of Contents**](#TOC)

**SMARTKEM, INC.**

**Notes to the Unaudited Condensed Consolidated Financial Statements**

Right of use lease assets and lease liabilities for the Company's operating leases were recorded in the unaudited condensed consolidated balance sheet as follows:

---

| | | |
|:---|:---|:---|
|  | **September 30,**  | **December 31,**  |
| ***(in thousands)*** | **2025** | **2024** |
| **Assets** |  |  |
| &nbsp;&nbsp;Right of use assets - Operating Leases | $663 | $120 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total lease assets | $663 | $120 |
| **Liabilities** |  |  |
| &nbsp;&nbsp;Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Lease liability, current - Operating Leases | $274 | $47 |
| &nbsp;&nbsp;Noncurrent liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Lease liability, non-current - Operating Leases | 376 | 25 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total lease liabilities | $650 | $72 |

---

The Company had no right of use lease assets or lease liabilities classified as financing leases as of September 30, 2025 and December 31, 2024.

The table below presents certain information related to the cash flows for the Company's operating leases for the periods ended:

---

| | | |
|:---|:---|:---|
|  | **September 30,**  | **September 30,**  |
| ***(in thousands)*** | **2025** | **2024** |
| Operating cash outflows from operating leases | $145 | $166 |
| Supplemental non-cash amounts of operating lease liabilities arising from obtaining right of use assets | $706 | $82 |

---

The table below presents certain information related to the weighted average remaining lease term and the weighted average discount rate for the Company's operating leases as of the period ended:

---

| | |
|:---|:---|
|  | **September 30,**  |
|  | **2025** |
| Weighted average remaining lease term (in years) – operating leases | 2.5 |
| Weighted average discount rate – operating leases | 10.64% |

---

Remaining maturities of the Company's operating leases, excluding short-term leases, are as follows:

---

| | |
|:---|:---|
|  | **September 30,**  |
| ***(in thousands)*** | **2025** |
| &nbsp;&nbsp;2025 | $80 |
| &nbsp;&nbsp;2026 | 328 |
| &nbsp;&nbsp;2027 | 309 |
| &nbsp;&nbsp;2028 | 23 |
| Total undiscounted lease payments | 740 |
| &nbsp;&nbsp;Less imputed interest | (90) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total net lease liabilities | $650 |

---

7.&nbsp;&nbsp;&nbsp;&nbsp;CONTINGENCIES

#### Legal proceedings
In the normal course of business, the Company may become involved in legal disputes regarding various litigation matters. In the opinion of management, any potential liabilities resulting from such claims would not have a material effect on the interim condensed consolidated financial statements.

[**Table of Contents**](#TOC)

**SMARTKEM, INC.**

**Notes to the Unaudited Condensed Consolidated Financial Statements**

8.&nbsp;&nbsp;&nbsp;&nbsp;STOCKHOLDERS' EQUITY

***Preferred Stock***

Pursuant to the terms of the Series A-1 Certificate of Designation, on May 7, 2025, the remaining 856 outstanding shares of Series A-1 Preferred Stock automatically converted into an aggregate of 690,788 shares of common stock and pre-funded Class C Warrants to purchase 1,282,412 shares of common stock. The Company filed a Certificate of Elimination with respect to the Series A-1 Certificate of Designation, pursuant to which, effective May 7, 2025, all matters set forth in the Series A-1 Certificate of Designation were eliminated from the Company's Amended and Restated Certificate of Incorporation.

As of September 30, 2025, there were no shares of Series A-1 Preferred Stock outstanding.

***Common Stock***

*Common Stock Issued to Vendors for Services*

During the nine months ended September 30, 2025, 190,000 shares of our common stock were issued to a vendor in consideration for services provided.

***Common Stock Warrants***

A summary of the Company's warrants to purchase common stock activity is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | <br>**Number of**<br>**Shares** | <br>**Exercise Price**<br>**per Share** | <br>**Weighted-**<br>**Average**<br>**Exercise**<br>**Price** | **Weighted-**<br>**Average**<br>**Remaining**<br>**Contractual**<br>**Term**<br>**(Years)** |
| Warrants outstanding at January 1, 2025 | 5171430 | $0.35 - $70.00 | $4.94 | 2.26 |
| &nbsp;&nbsp;Issued |  |  |  |  |
| &nbsp;&nbsp;Exercised | (160) |  | 0.35 |  |
| &nbsp;&nbsp;Expired |  |  |  |  |
| Warrants outstanding at September 30, 2025 | 5171270 | $0.35 - $70.00 | $4.94 | 1.52 |

---

During the quarter ended June 30, 2025, 160 Class B Warrants were exercised at an exercise price of $0.35.

A summary of the Company's pre-funded warrants to purchase common stock activity is as follows:

---

| | | |
|:---|:---|:---|
|  | <br>**Number of**<br>**Shares** | **Weighted-**<br>**Average**<br>**Exercise**<br>**Price** |
| Pre-funded warrants outstanding at January 1, 2025 | 2318502 | $0.0064 |
| &nbsp;&nbsp;Issued | 1282412 | 0.0001 |
| &nbsp;&nbsp;Exercised | (1133977) | 0.0001 |
| &nbsp;&nbsp;Expired |  |  |
| Pre-funded warrants outstanding at September 30, 2025 | 2466937 | $0.0060 |

---

During the quarter ended June 30, 2025, 1,282,412 Class C Warrants were issued at an exercise price of $0.0001. During the quarter ended September 30, 2025, 1,133,977 prefunded warrants were exercised at an exercise price of $0.0001.

[**Table of Contents**](#TOC)

**SMARTKEM, INC.**

**Notes to the Unaudited Condensed Consolidated Financial Statements**

**9. SHARE-BASED COMPENSATION**

On February 23, 2021, the Company approved the 2021 Equity Incentive Plan (the "2021 Plan"), in which a maximum aggregate number of shares of common stock that may be issued under the 2021 Plan is 65,000 shares. Subject to the adjustment provisions of the 2021 Plan, the number of shares of the Company's common stock available for issuance under the 2021 Plan will also include an annual increase on the first day of each fiscal year beginning with 2022 fiscal year and ending on the Company's 2031 fiscal year in an amount equal to the least of: 1) 65,000 shares of the Company's common stock; 2) four percent (4%) of the outstanding shares of the Company's common stock on the last day of the immediately preceding fiscal year; or 3) such number of shares of the Company's common stock as the administrator may determine.

At the 2023 Annual Meeting, the Company's stockholders approved an amendment (the "2023 Plan Amendment") to the Company's 2021 Plan, increasing the number of the shares of common stock reserved for issuance under the 2021 Plan from 125,045 shares to 743,106 shares. The Company's Board of Directors had previously approved the 2023 Plan Amendment, subject to stockholder approval.

At the 2025 Annual Meeting, the Company's stockholders approved an amendment (the "2025 Plan Amendment") to the Company's 2021 Plan, (i) increasing the number of the shares of common stock, reserved for issuance thereunder from 843,692 shares to 1,643,692 shares, and (ii) setting the "evergreen" share amount to 4% of the outstanding shares of common stock. The Company's Board of Directors had previously approved the 2025 Plan Amendment, subject to stockholder approval.

Determining the appropriate fair value of share-based awards requires the input of subjective assumptions, including the fair value of the Company's common stock, and for share options, the expected life of the option, and expected share price volatility. The Company uses the Black-Scholes option pricing model to value its share option awards. The assumptions used in calculating the fair value of share-based awards represent management's best estimates and involve inherent uncertainties and the application of management's judgment. As a result, if factors change and management uses different assumptions, the share-based compensation expense could be materially different for future awards. Options granted under the 2021 Plan for nine months ended September 30, 2025 and 2024, were valued using the Black-Scholes option-pricing model with the following assumptions:

---

| | | | |
|:---|:---|:---|:---|
|  | **September 3,**<br>**2025** | **April 15,**<br>**2025** | **June 14,**<br>**2024** |
| Expected term (years) | 5.75 | 5.75 | 5.73 |
| Risk-free interest rate | 3.78% | 4.04% | 4.21% |
| Expected volatility | 50% | 50% | 50% |
| Expected dividend yield | 0% | 0% | 0% |

---

During the nine months ended September 30, 2025, the Company issued options for 1,031,214 shares of common stock to employees, directors and consultants. The options vest over a period of three years and expire on the ten-year anniversary of the grant date. The options for the 710,268 shares issued on April 15, 2025 have an exercise price of $2.51. The options for the 320,946 shares issued on September 3, 2025 have an exercise price of $1.16. The weighted average grant-date fair value of stock options granted during the nine months ended September 30, 2025 and 2024 was $1.07 and $3.35, respectively.

[**Table of Contents**](#TOC)

**SMARTKEM, INC.**

**Notes to the Unaudited Condensed Consolidated Financial Statements**

The following table reflects share activity under the share option plans for the nine months ended September 30, 2025:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | <br>**Number of**<br>**Shares** | <br>**Weighted-**<br>**Average**<br>**Exercise**<br>**Price** | **Weighted-**<br>**Average**<br>**Remaining**<br>**Contractual**<br>**Term**<br>**(Years)** | <br>**Weighted-**<br>**Average**<br>**Fair Value at**<br>**Grant Date** | <br>**Aggregate**<br>**Intrinsic**<br>**Value**<br>***(in thousands)*** |
| Options outstanding at January 1, 2025 | 619910 | $12.31 | 9.06 | $3.54 |  |
| &nbsp;&nbsp;Granted | 1031214 | 2.09 |  |  |  |
| &nbsp;&nbsp;Exercised |  |  |  |  |  |
| &nbsp;&nbsp;Cancelled/Forfeited | (8002) | 10.48 |  |  |  |
| &nbsp;&nbsp;Expired |  |  |  |  |  |
| Options outstanding at September 30, 2025 | 1643122 | $5.90 | 9.21 | $3.12 |  |
| Options exercisable at September 30, 2025 | 704847 | $8.98 | 8.92 |  | $53.20 |

---

Stock-based compensation is included in the unaudited interim condensed consolidated statements of operations as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,**  | **Three Months Ended September 30,**  | **Nine Months Ended September 30,**  | **Nine Months Ended September 30,**  |
| ***(in thousands)*** | **2025** | **2024** | **2025** | **2024** |
| Research and development | $72 | $79 | $219 | $175 |
| General and administration | 188 | 178 | 550 | 396 |
| &nbsp;&nbsp;Total | $260 | $257 | $769 | $571 |

---

Total compensation cost related to non-vested stock option awards not yet recognized as of September 30, 2025 was $2.1 million and will be recognized on a straight-line basis through the end of the vesting periods in September 2028. The amount of future stock option compensation expense could be affected by any future option grants or by any forfeitures.

**10. BASIC AND DILUTED LOSS PER SHARE**

Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period, without consideration of potentially dilutive securities, except for those shares that are issuable for little or no cash consideration. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all common stock options and warrants are generally deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal.

The following potentially dilutive securities were excluded from the computation of earnings per share as of September 30, 2025 and 2024 because their effects would be anti-dilutive:

---

| | | |
|:---|:---|:---|
|  | **September 30,**  | **September 30,**  |
|  | **2025** | **2024** |
| Common stock warrants | 4450324 | 1772829 |
| Assumed conversion of preferred stock |  | 97866 |
| Stock options | 1643122 | 632546 |
| &nbsp;&nbsp;Total | 6093446 | 2503241 |

---

11. DEFINED CONTRIBUTION PENSION

The Company operates a defined contribution pension scheme for its UK employees. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge

[**Table of Contents**](#TOC)

**SMARTKEM, INC.**

**Notes to the Unaudited Condensed Consolidated Financial Statements**

represents contributions payable by the Company to the fund. Pension cost is included in the unaudited interim condensed consolidated statements of operations as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,**  | **Three Months Ended September 30,**  | **Nine Months Ended September 30,**  | **Nine Months Ended September 30,**  |
| ***(in thousands)*** | **2025** | **2024** | **2025** | **2024** |
| Research and development | $49 | $23 | $107 | $64 |
| General and administration | 15 | 19 | 53 | 55 |
| &nbsp;&nbsp;Total | $64 | $42 | $160 | $119 |

---

**12. INCOME TAXES**

On July 4, 2025, the One Big Beautiful Bill Act was enacted, introducing significant changes to U.S. federal tax law, including modifications to corporate tax rates, deductions, and tax credit provisions. The Company is currently evaluating the provisions of the new law and assessing the potential impacts on its consolidated financial statements.

As of September 30, 2025, the Company has not completed its analysis and has therefore not recorded any material adjustments related to the new legislation. The final impact of the tax law may differ from the Company's current estimates as the assessment is completed and additional guidance, interpretations, or clarifications become available.

**13. SEGMENT REPORTING**

We manage our business activities on a consolidated basis and operate as a single operating segment: Semiconductor materials. Our revenue is mostly generated from R&D grants and R&D tax credits. The accounting policies of the semiconductor materials are the same as those described in Note 2 – Summary of Significant Accounting Policies.

Our CODM is our Chief Executive Officer and President, Ian Jenks. The CODM uses net loss, as reported on our Consolidated Statements of Comprehensive Income, in evaluating performance of the Semiconductor materials segment and determining how to allocate resources of the Company as a whole and making decisions on perspective joint development and collaboration agreements. The CODM does not review assets in evaluating the results of the Semiconductor materials segment, and therefore, such information is not presented.

The following table provides the net losses of the Semiconductor materials segment:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,**  | **Three Months Ended September 30,**  | **Nine Months Ended September 30,**  | **Nine Months Ended September 30,**  |
|  | **2025** | **2024** | **2025** | **2024** |
| Revenue | $81 | $— | $136 | $40 |
| Cost of revenue | 5 |  | 34 | 32 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 76 |  | 102 | 8 |
| Other operating income | 181 | 287 | 711 | 725 |
| &nbsp;&nbsp;Operating expenses |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 2056 | 1504 | 5979 | 3938 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 1331 | 1578 | 5700 | 4784 |
| &nbsp;&nbsp;&nbsp;&nbsp;(Gain)/loss on foreign currency transactions | 59 | 43 | (167) | 75 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 3446 | 3125 | 11512 | 8797 |
| Loss from operations | (3189) | (2838) | (10699) | (8064) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total non-operating income/(expense) | (731) | (4) | 2221 | 428 |
| Loss before income taxes | (3920) | (2842) | (8478) | (7636) |
| &nbsp;&nbsp;Income tax refund |  |  | 24 | (1) |
| Net loss | $(3920) | $(2842) | $(8454) | $(7637) |

---

[**Table of Contents**](#TOC)

**SMARTKEM, INC.**

**Notes to the Unaudited Condensed Consolidated Financial Statements**

**14. SUBSEQUENT EVENTS**

***Warrant Exercises***

On October 10, 2025, 179,924 shares of our common stock were issued upon the exercise of Class C Warrants.

On October 13, 2025, 99,996 shares of our common stock were issued upon the cashless exercise of 100,000 Class C Warrants.

***Stock Issuances***

On October 7, 2025 we entered into agreements with four consulting firms to provide investor relations related services to the Company, and in consideration for such services, agreed to issue up 750,000 shares (the "Shares") of common stock of the Company, par value $0.0001 per share, subject to certain restrictions. The Shares will be issued and sold in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended, afforded by Section 4(a)(2) of the Securities Act.

***Jericho Transaction***

On October 6, 2025, we entered into the LOI with Jericho , an energy innovation company, to pursue the Proposed Transaction. Under the LOI, the Proposed Transaction would be structured as an all-stock business combination, effected through either a share exchange or statutory merger, pursuant to which our company would be the surviving legal entity and would continue as a publicly listed company on Nasdaq (such surviving company, the Combined Company). Upon the closing of the Proposed Transaction, Jericho stockholders would own 65% and our stockholders prior to the Proposed Transaction would own 35% of the fully diluted issued and outstanding equity securities of the Combined Company, subject to adjustment in certain circumstances. Brian Williamson, the current chief executive officer of Jericho, would become the chief executive officer of the Combined Company, and the board of directors of the Combined Company would be reconstituted to include a majority of members designated by Jericho, subject to compliance with applicable requirements of Nasdaq and the SEC.

The LOI is non-binding, and there can be no assurance that we and Jericho will ultimately enter into a definitive agreement for the Proposed Transaction, that the Proposed Transaction will be consummated, or as to the timing or ultimate terms of any Proposed Transaction that may occur. Both we and Jericho will need significant additional capital to complete the negotiation of the Proposed Transaction, obtain any required stockholder approvals and ultimately complete the Proposed Transaction. The closing of the Proposed Transaction would be subject to significant closing conditions, including the negotiation of the definitive agreement, the satisfactory completion of due diligence, required board and stockholder approvals, and approval of continued listing by Nasdaq.

In the LOI, we and Jericho have agreed to a 60-day exclusivity period to negotiate the terms of a definitive agreement, which exclusivity period is terminable by either party under certain circumstances including, in the case of Jericho, if we do not purchase Jericho common shares having a value of at least $500,000 on or prior to November 30, 2025. So long as the LOI is still in effect, upon the earlier of (i) our chief financial officer's good faith determination that we have regained compliance with Nasdaq's minimum stockholders' equity requirement and (ii) our issuance of securities (including upon exercise of outstanding convertible securities) for aggregate gross proceeds of not less than $5,000,000, we will purchase from treasury Jericho common shares in an amount equal to the greater of (a) $500,000 and (b) 10% of the gross proceeds of such issuances, subject to a cap of $1,000,000. There can be no assurance that the circumstances necessary for us to satisfy the requirements for completion of the investment will occur.

***June 2023 Purchase Agreement Amendment***

On October 13, 2025, we entered into an Amendment Agreement with certain holders (the "Holders") of securities issued in our June 2023 private placement, pursuant to which the Holders agreed to amend the Purchase Agreement, dated June 14, 2023 (as previously amended, the "June 2023 Purchase Agreement") to

[**Table of Contents**](#TOC)

**SMARTKEM, INC.**

**Notes to the Unaudited Condensed Consolidated Financial Statements**

lower the price at which a Lower Price Issuance (as defined in the June 2023 Purchase Agreement) would be deemed to occur from $4.00 to $2.75.

***Senior Secured Loan***

On October 31, 2025, the Company entered into a securities purchase agreement (the "Purchase Agreement") with certain purchasers (the "Purchasers"), pursuant to which the Company issued and sold to the Purchasers in a private placement: (i) Senior Secured Notes (the "Notes") in the aggregate principal amount of $1,100,000 and (ii) warrants (the "Warrants") exercisable for up to an aggregate of 400,000 shares of the Company's common stock, at an exercise price of $2.75 per share for an aggregate purchase price of $1,000,000.

The Notes mature on April 30, 2026 and do not bear interest prior to an event of default. If an event of default occurs, interest will accrue at an interest rate equal to the lesser of 10% of the accrued principal amount due and owing under the Note per annum or the maximum rate permitted under applicable law. The Notes are not convertible into shares of the Company's common stock.

In connection with the issuance of the Notes, on October 31, 2025, the Company and its subsidiaries entered into a security agreement with The Hewlett Fund LP, as collateral agent (the "Security Agreement"). Pursuant to the Security Agreement, each of the Company and its subsidiaries granted the collateral agent a security interest in substantially all of their assets for the benefit of the Purchasers.

The Warrants have an exercise price of $2.75 per share. The Warrants are exercisable upon issuance and will expire five (5) years from the date of issuance. The Warrants are exercisable in whole or in part in cash. If at the time of exercise more than six months after the issuance date there is no effective registration statement registering, or the prospectus contained therein is not available for the resale or other disposition of the shares of common stock underlying the Warrants, then the Warrants may also be exercised, in whole or in part, at such time by means of a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the Warrant.

A holder of Warrants will not have the right to exercise any portion of its Warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or, at the election of the holder prior to issuance of the Warrants, 9.99%) of the number of shares of the Company's common stock outstanding immediately after giving effect to such exercise. A holder may increase or decrease the beneficial ownership limitation up to 9.99%, provided, however, that any increase in the beneficial ownership limitation shall not be effective until 61 days following notice of such change to us. In the event of certain fundamental transactions, the holder of the Warrants will have the right to receive the Black Scholes Value of its Warrants calculated pursuant to a formula set forth in the Warrants.

The securities described above were sold to the Purchasers without registration under the Securities Act or state securities laws in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws.

[**Table of Contents**](#TOC)

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*The following discussion and analysis of the financial condition and results of operations of SmartKem, Inc. ("SmartKem" or the "Company") should be read in conjunction with the unaudited interim condensed consolidated financial statements and notes thereto contained in Item 1 of Part I of this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 to provide an understanding of its results of operations, financial condition and cash flows.*

*All references in this Quarterly Report to "we," "our," "us" and the "Company" refer to SmartKem, Inc., and its subsidiaries unless the context indicates otherwise.*

#### DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains certain "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 with respect to our business, financial condition, liquidity, and results of operations. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "could," "would," "will," "may," "can," "continue," "potential," "should," and the negative of these terms or other comparable terminology often identify forward-looking statements. Statements in this Quarterly Report on Form 10-Q (this "Report") that are not historical facts are hereby identified as "forward-looking statements" for the purpose of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Section 27A of the Securities Act of 1933, as amended (the "Securities Act"). These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from the results contemplated by the forward-looking statements, including the risks discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the "10-K") in Item 1A under "Risk Factors" and the risks detailed from time to time in our future reports filed with the Securities and Exchange Commission (the "SEC"). These forward-looking statements include, but are not limited to, statements about:

● the implementation of our business model and strategic plans for our business, technologies and products;

● the rate and degree of market acceptance of any of our products or organic semiconductor technology in

general, including changes due to the impact of (i) new semiconductor technologies, including MicroLED technology, (ii) the performance of organic semiconductor technology, whether perceived or actual, relative to competing semiconductor materials, and (iii) the performance of our products, whether perceived or actual, compared to competing silicon-based and other products;

● the timing and success of our, and our customers', product releases;

● our ability to develop new products and technologies;

● our ability to meet management goals;

● our ability to regain and maintain compliance with the continued listing requirements of The Nasdaq Stock Market LLC ("Nasdaq");

● our estimates of our expenses, ongoing losses, future revenue and capital requirements, including

our needs for additional financing;

● our ability to obtain additional funds for our operations and our intended use of any such funds;

● our ability to remain eligible on an over-the-counter quotation system if our common stock is delisted from Nasdaq;

● our receipt and timing of any royalties, milestone payments or payments for products, under any current or future collaboration, license or other agreements or arrangements;

● our ability to obtain and maintain intellectual property protection for our technologies and products and our ability to operate our business without infringing the intellectual property rights of others;

● the strength and marketability of our intellectual property portfolio;

● our dependence on current and future collaborators for developing, manufacturing or otherwise bringing our products to market;

● the ability of our third-party supply and manufacturing partners to meet our current and future business needs;

● our exposure to risks related to international operations;

● our dependence on third-party fabrication facilities;

● our relationships with our executive officers, directors, and significant stockholders;

[**Table of Contents**](#TOC)

● our expectations regarding our classification as a "smaller reporting company," as defined under the Exchange Act, and an "emerging growth company" under the Jumpstart Our Business Startups Act (the "JOBS Act") in future periods;

● our future financial performance;

● the competitive landscape of our industry;

● the impact of government regulation and developments relating to us, our competitors, or our industry; and

● other risks and uncertainties, including those listed under the caption "Risk Factors" in our 10-K.

These statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under "Risk Factors" in our 10-K and in this Report and elsewhere in this Report.

Any forward-looking statement in this Report reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our business, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Report and the documents that we reference in this Report and have filed with the SEC as exhibits hereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

**Company Overview**

We are seeking to change the world of electronics with a new class of transistor developed using our proprietary advanced semiconductor materials that we believe has the potential to revolutionize the display industry. Our TRUFLEX® semiconductor polymers enable low temperature printing processes that are compatible with existing manufacturing infrastructure to deliver low-cost, high-performance displays. Our semiconductor platform can be used in a range of display technologies including MicroLED, LCD and AMOLED, as well as in applications in advanced computer and AI chip packaging, sensors, and logic.

We design and develop our materials at our research and development facility in Manchester, UK and provide prototyping services at the Centre for Process Innovation ("CPI") in Sedgefield, UK. We also operate a field application office in Hsinchu, Taiwan, close to our collaboration partner, The Industrial Technology Research Institute of Taiwan ("ITRI"). With our collaboration partners, we are developing a commercial-scale production process and Electronic Design Automation (EDA) tools for our materials to demonstrate the commercial viability of manufacturing a new generation of displays using our materials. We have an extensive IP portfolio including 140 granted patents across 17 patent families, 14 pending patents and 40 codified trade secrets.

Since our inception in 2009, we have devoted substantial resources to the research and development of materials and production processes for the manufacture of organic thin film transistors and the enhancement of our intellectual property.

Our loss before income taxes was $8.5 million and $7.6 million for the nine months ended September 30, 2025 and 2024. As of September 30, 2025, our accumulated deficit was $123.1 million. Substantially all our operating losses have resulted from expenses incurred in connection with research and development activities and from general and administrative costs associated with our operations.

As a result of our need for additional capital, we have significantly curtailed our operations and delayed payments to our vendors as a part of our plan to conserve cash. Consequently, our accounts payable have increased significantly since September 30, 2025. We will require significant additional capital in order to pay vendors and to resume normal operations.

[**Table of Contents**](#TOC)

**Results of Operations for the three and nine months ended September 30, 2025**

***Three months ended September 30, 2025 compared with three months ended September 30, 2024***

*Revenue and Cost of revenue*

We had revenue of $81.0 thousand and cost of revenue of $5.0 thousand in the three months ended September 30, 2025, compared to no revenue or cost of revenue for the same period of 2024. Both revenue and related cost of revenue for the three months ended September 30, 2025 are a result of sales of OTFT backplanes and TRUFLEX® materials for customer assessment and development purposes.

*Other operating income*

Other operating income was $0.2 million in the three months ended September 30, 2025, compared to $0.3 million in the same period of 2024. The primary source of other operating income is related to multiple research grants from Innovate UK and research and development tax credits.

*Operating expenses*

Operating expenses were $3.4 million for the three months ended September 30, 2025, compared to $3.1 million for the three months ended September 30, 2024, an increase of $0.3 million, or 10.3%.

Research and development expenses are incurred for the development and process validation for TRUFLEX® inks to make OTFT circuits and OTFT based display concepts integrating novel display technology, and to provide dielectric solutions for packaging applications. The expenses consist primarily of payroll, technical facilities overheads, and development consumables costs. Research and development expenses were $2.1 million for the three months ended September 30, 2025, compared to $1.5 million for the same period of 2024, an increase of $0.6 million, or 36.7%. This increase primarily resulted from a $0.7 million increase in costs in the third quarter of 2025 pursuant to the terms of the extension of the CPI Framework agreement. As noted above, we expect those increased costs to continue in future periods. The increase in research and development expenses also resulted in part from higher personnel expenses. The research and development expenses represent 59.7% and 48.1% of the total operating expenses for the three months ended September 30, 2025 and 2024, respectively.

General and administrative expenses consist primarily of payroll and professional services such as investor relations, accounting and legal services. General and administrative expenses were $1.3 million for the three months ended September 30, 2025, compared to $1.6 million for the same period of 2024, a decrease of $0.3 million, or 15.7%. These expenses represent 38.6% and 50.5% of our total operating expenses for the three months ended September 30, 2025 and 2024, respectively. This decrease primarily resulted from a decrease in professional service fees principally related to investor relations support and consulting agreements, including $34 thousand in non-cash expenses. As a result of the stock issuances described under Note 14. Subsequent Events – Stock Issuances, we expect that our investor relations expenses will increase significantly in the fourth quarter of 2025.

*Non-Operating income/(expense)*

Non-operating expense was $0.7 million for the three months ended September 30, 2025, with no comparable expense for the same period of 2024, for an increase of $0.7 million. The increase is primarily due to a loss on foreign currency related to the revaluation of the intercompany loans and related interest. The change in the foreign exchange spot rate of 1.3434 as of September 30, 2025 compared to 1.3724 as of June 30, 2025 resulted in a foreign exchange loss. The offset of this loss is recorded in other comprehensive income.

***Nine months ended September 30, 2025 compared with nine months ended September 30, 2024***

*Revenue and Cost of revenue*

We had revenue of $136.0 thousand and $40.0 thousand and cost of revenue of $34.0 thousand and $32.0 thousand in the nine months ended September 30, 2025 and 2024, respectively. Both revenue and related cost of

[**Table of Contents**](#TOC)

revenue for the nine months ended September 30, 2025 and 2024 resulted from sales of OTFT backplanes and TRUFLEX® materials for customer assessment and development purposes.

*Other operating income*

Other operating income was $0.7 million in the nine months ended September 30, 2025, compared to $0.7 million in the same period of 2024. The primary source of other operating income is related to multiple research grants from Innovate UK and research and development tax credits.

*Operating expenses*

Operating expenses were $11.5 million for the nine months ended September 30, 2025 compared to $8.8 million for the nine months ended September 30, 2024, an increase of $2.7 million, or 30.9%.

Research and development expenses are incurred for the development and process validation for TRUFLEX® inks to make OTFT circuits and OTFT based display concepts integrating novel display technology and provide dielectric solutions for packaging applications. The expenses consist primarily of payroll, technical facilities overheads, and development consumables costs. Research and development expenses were $6.0 million for the nine months ended September 30, 2025, compared to $3.9 million for the same period of 2024, an increase of $2.1 million, or 51.8%. This increase primarily resulted from a $1.7 million increase in costs in the second and third quarters of 2025 pursuant to the terms of the extension of the CPI Framework agreement. As noted above, we expect those increased costs to continue in future periods. The increase in research and development expenses also resulted in part from higher personnel expenses. The research and development expenses represent 51.9% and 44.8% of the total operating expenses for the nine months ended September 30, 2025 and 2024, respectively.

General and administrative expenses consist primarily of payroll and professional services such as investor relations, accounting and legal services. General and administrative expenses were $5.7 million for the nine months ended September 30, 2025, compared to $4.8 million for the same period of 2024, an increase of $0.9 million, or 19.1%. These expenses represent 49.5% and 54.4% of our total operating expenses for the nine months ended September 30, 2025 and 2024, respectively. This increase primarily resulted from an increase in professional service fees principally related to investor relations support and consulting agreements, including $0.4 million in non-cash expenses. As a result of the stock issuances described under Note 14. Subsequent Events – Stock Issuances, we expect that our investor relations expenses will increase significantly in the fourth quarter of 2025.

*Non-Operating income/(expense)*

Non-operating income was $2.2 million for the nine months ended September 30, 2025, compared to non-operating income of $0.4 million for the same period of 2024, an increase of $1.8 million, or 418.9%. $2.5 million of the increase is primarily due to a gain on foreign currency. The increase is primarily due to a gain on foreign currency related to the revaluation of the intercompany loans and related interest. The change in the foreign exchange spot rate of 1.3434 as of September 30, 2025 compared to 1.2567 as of December 31, 2024 resulted in a foreign exchange gain. The offset of this gain is recorded in other comprehensive income. Such gain was offset by a loss of $0.7 million in the nine months ended September 30, 2024 related to changes in certain of our warrants that occurred as a result of the listing of our common stock on the Nasdaq Capital Market on May 31, 2024. Those warrants were accounted for as an equity instrument beginning on that date and as a result there was no similar gain or loss in the same period of 2025.

**Liquidity and Capital Resources**

As of September 30, 2025, our cash and cash equivalents were $0.9 million compared with $7.1 million as of December 31, 2024. We believe our cash balance at September 30, 2025 will not be sufficient to fund our operations through December 31, 2025 and that we will require additional capital funding to continue our operations and research development activity. In the event that we are unable to raise additional capital in the near term, we may have to curtail our operations or seek protection under applicable bankruptcy or insolvency laws. As described under Note 14. Subsequent Events --Senior Secured Loan, on October 31, 2025, we obtained $1,000,000 of bridge financing in exchange for the issuance of $1,100,000 principal amount of its Senior

[**Table of Contents**](#TOC)

Secured Notes due April 30, 2026 (the "Senior Secured Notes") and five-year warrants to purchase up to 400,000 shares of common stock at an exercise price of $2.75 per share. There can be no assurance that we will be able to raise sufficient funds to repay the Senior Secured Notes which are secured by substantially all of our company and its subsidiaries.

As a result of our need for additional capital, we have significantly curtailed our operations and delayed payments to our vendors as a part of our plan to conserve cash. Consequently, our accounts payable have increased significantly since September 30, 2025. We will require significant additional capital in order to pay vendors and to resume normal operations.

Our expected cash payments over the next twelve months include (a) $4.9 million to satisfy accounts payable and accrued expenses and (b) $0.3 million to satisfy the lease liabilities. Additional expected cash payments beyond the next twelve months include $0.4 million of lease liabilities.

Beyond our near term need for capital, our future viability is dependent on our ability to raise additional capital to fund our operations. We will need to obtain additional funds to satisfy our operational needs and to fund our sales and marketing efforts, research and development expenditures, and business development activities. Until such time, if ever, as we can generate sufficient cash through revenue, management's plans are to finance our working capital requirements through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. If we raise additional funds by issuing equity securities, our existing security holders will likely experience dilution. If we borrow money, the incurrence of indebtedness would result in increased debt service obligations and could require us to agree to operating and financial covenants that could restrict our operations. If we enter into a collaboration, strategic alliance or other similar arrangement, we may be forced to give up valuable rights. There can be no assurance however that such financing will be available in sufficient amounts, when and if needed, on acceptable terms or at all. The precise amount and timing of the funding needs cannot be determined accurately at this time, and will depend on a number of factors, including the market demand for our products and services, the quality of product development efforts, management of working capital, and continuation of normal payment terms and conditions for purchase of services.

**Cash Flow**

Net cash used in operating activities was $6.3 million for the nine months ended September 30, 2025, compared to $7.0 million for the nine months ended September 30, 2024, a decrease of $0.7 million. The decrease resulted primarily from an increase in our comprehensive net loss, offset in part by a significant increase in accounts payable.

Net cash used in investing activities was $0.1 million for the nine months ended September 30, 2025.

During the nine months ended September 30, 2025, we had no cash flows financing activities.

**Contractual Payment Obligations**

Our principal commitments primarily consist of obligations under leases for office space and purchase commitments in the normal course of business for research and development facilities and services, communications infrastructure, and administrative services. We expect to fund these commitments from our cash balances and working capital.

**Critical Accounting Estimates**

We prepare our consolidated financial statements in accordance with U.S. generally accepted accounting principles ("GAAP"), which require our management to make estimates that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the balance sheet dates, as well as the reported amounts of revenues and expenses during the reporting periods. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations would be affected. We base our estimates on our own historical experience and other assumptions that we believe are reasonable after taking account of our circumstances and expectations for the future based on available information. We evaluate these estimates on an ongoing basis.

[**Table of Contents**](#TOC)

We consider an accounting estimate to be critical if: (i) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (ii) changes in the estimate that are reasonably likely to occur from period to period or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations.

Management has discussed the development and selection of these critical accounting estimates with the Audit Committee of our Board of Directors. In addition, there are other items within our financial statements that require estimation but are not deemed critical as defined above. Changes in estimates used in these and other items could have a material impact on our financial statements.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk**

Not applicable.

**Item 4. Controls and Procedures**

*Inherent Limitations on Effectiveness of Controls*

Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well-designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.

*Evaluation of Disclosure Controls and Procedures*

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures.

Our management, with the participation of its Chief Executive Officer and Chief Financial Officer, performed an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) of the Exchange Act). Based upon, and as of the date of, this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2025.

*Changes in Internal Controls over Financial Reporting*

There were no other changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act) that occurred during the period covered by this Report that have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

[**Table of Contents**](#TOC)

**PART II — OTHER INFORMATION**

**Item 1. Legal Proceedings**

None

**Item 1A. Risk Factors**

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, "Item 1A. Risk Factors" in the 10-K, which could materially affect our business, financial condition or future results. The risks described in the 10-K may not be the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

There have been no material changes to the risk factors previously disclosed in the 10-K.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

None.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not Applicable.

**Item 5. Other Information**

None of the Company's directors and officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company's fiscal quarter ended September 30, 2025 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).

**Item 6. Exhibits**

See Exhibit Index.

[**Table of Contents**](#TOC)

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 2.1 \* | [Share Exchange Agreement, dated as of February 23, 2021, among the Registrant, SmartKem Limited and the shareholders of SmartKem Limited (incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed on February 24, 2021)](https://www.sec.gov/Archives/edgar/data/1817760/000110465921027574/tm216420d1_ex2-1.htm) |
| 3.1 | [Amended and Restated Certificate of Incorporation of the Registrant, as amended to date (incorporated by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q filed on May 13, 2025)](https://www.sec.gov/Archives/edgar/data/1817760/000155837025007572/smtk-20250331xex3d1.htm) |
| 3.2 | [Amended and Restated Bylaws of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.4 to the Company's Current Report on Form 8-K filed on February 24, 2021)](https://www.sec.gov/Archives/edgar/data/1817760/000110465921027574/tm216420d1_ex3-4.htm) |
| 4.1 | [Form of Warrant (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on November 3, 2025)](https://www.sec.gov/Archives/edgar/data/1817760/000110465925105530/tm2528045d4_ex4-1.htm) |
| 10.1# | [Amendment No. 1 to Employment Agreement, dated September 3, 2025, by and between SmartKem, Inc. and Ian Jenks (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on September 5, 2025)](https://www.sec.gov/Archives/edgar/data/1817760/000110465925087838/tm2525176d1_ex10-1.htm)  |
| 10.2 | [Amendment Agreement, dated October 13, 2025 (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on October 14, 2025)](https://www.sec.gov/Archives/edgar/data/1817760/000110465925099052/tm2528045d3_ex10-1.htm) |
| 10.3 | [Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on November 3, 2025)](https://www.sec.gov/Archives/edgar/data/1817760/000110465925105530/tm2528045d4_ex10-1.htm) |
| 10.4 | [Form of Senior Secured Note (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on November 3, 2025)](https://www.sec.gov/Archives/edgar/data/1817760/000110465925105530/tm2528045d4_ex10-2.htm) |
| 10.5 | [Security Agreement, dated October 31, 2025, by and between SmartKem, Inc. and The Hewlett Fund LP, as collateral agent (incorporated by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed on November 3, 2025)](https://www.sec.gov/Archives/edgar/data/1817760/000110465925105530/tm2528045d4_ex10-3.htm) |
| 31.1† | [Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](smtk-20250930xex31d1.htm) |
| 31.2† | [Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](smtk-20250930xex31d2.htm) |
| 32.1†† | [Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](smtk-20250930xex32d1.htm) |
| 32.2†† | [Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](smtk-20250930xex32d2.htm) |
| 101.INS† | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |
| 101.SCH† | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL† | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF† | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB† | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE† | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104† | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |

---

# Indicates management contract or compensatory plan.

† Filed herewith.

†† This certification is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the registrant specifically incorporates it by reference.

[**Table of Contents**](#TOC)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, duly authorized.

Date: November 13, 2025

---

| | |
|:---|:---|
| **SMARTKEM, INC.** | **SMARTKEM, INC.** |
| By: | /s/ Ian Jenks |
| Name: | Ian Jenks |
| Title: | Chief Executive Officer and Chairman of the Board |
|  | (Principal Executive Officer) |
| By: | /s/ Barbra C. Keck |
| Name: | Barbra C. Keck |
| Title: | Chief Financial Officer |
|  | (Principal Financial Officer) |

---

## Exhibit 31.1

**Exhibit 31.1** 

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

**TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Ian Jenks, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q of SmartKem, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 13, 2025

---

| | |
|:---|:---|
| By: | /s/ Ian Jenks |
| Name: | Ian Jenks |
| Title: | Chief Executive Officer |

---

------

## Exhibit 31.2

**Exhibit 31.2** 

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

**TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Barbra C. Keck, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q of SmartKem, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 13, 2025

---

| | | |
|:---|:---|:---|
| J.<br>|  |  |
|  | By: | /s/ Barbra C. Keck |
|  | Name: | Barbra C. Keck |
|  | Title: | Chief Financial Officer |

---

------

## Exhibit 32.1

**Exhibit 32.1** 

**Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350,** 

**As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002** 

In connection with this Quarterly Report of SmartKem, Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2025 (the "Report") as filed with the Securities and Exchange Commission on the date hereof, the undersigned, Ian Jenks, Chief Executive Officer of the Company, hereby certifies, to the knowledge of the undersigned, pursuant to 18 U.S.C. Section 1350, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 13, 2025

---

| | |
|:---|:---|
| By: | /s/ Ian Jenks |
| Name: | Ian Jenks |
| Title: | Chief Executive Officer |

---

------

## Exhibit 32.2

**Exhibit 32.2** 

**Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350,** 

**As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002** 

In connection with this Quarterly Report of SmartKem, Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2025 (the "Report") as filed with the Securities and Exchange Commission on the date hereof, the undersigned, Barbra C. Keck, Chief Financial Officer of the Company, hereby certifies, to the knowledge of the undersigned, pursuant to 18 U.S.C. Section 1350, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 13, 2025

---

| | | |
|:---|:---|:---|
| J. <br>|  |  |
|  | By: | /s/ Barbra C. Keck |
|  | Name: | Barbra C. Keck |
|  | Title: | Chief Financial Officer |

---

------